Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The event will take place in Hyatt Regency İstanbul - Ataköy. One of the largest metropols in the world, İstanbul is a strategical intersection point for almost everything. This distinctive city is one of the best options to host distinctive people at a special event.
We are the global healthcare technology leader, with more than 90,000 people across 150 countries. We innovate solutions that treat more than 70 health conditions, from Parkinson’s to diabetes. And while our healthcare technologies transform the lives of two people every second, every hour, of every day, expect more from us. We keep expanding our impact far beyond. In everything we do, we are engineering the extraordinary.
The rich history of diabetes within Medtronic is a distinctive story itself. This event will host the most distinctive healthcare professionals with the most innovative content. As this is the first Diabetes Innovation Summit organized by Medtronic, we are already thrilled to be sharing knowledge and expanding the opportunities about the future of diabetes. This extraordinary event needed an extraordinary name to tell its story.
DISTINCT experts who will share their knowledge during the first
Diabetes Innovation Summit
Consultant and Head of
Department of Pediatric and
Head, Chair of Pediatrics, and
Professor of Paediatrics at
Faculty of Medicine,
University of Ljubljana
Chair Professor in Medicine at the
Institute of Medical Sciences and
Director of the Diabetes,
Endocrinology and Metabolism
Research Centre at the
University Hospital of Örebro,
Chief Medical Officer,
Global Medical and
Past-President, Endocrine Society
Professor of Medicine,
University of the Health Sciences
Professor of Pediatrics
in Pediatric Endocrinology
and Diabetes Department
at Ege University Faculty
of Medicine, İzmir, Türkiye
Consultant Pediatric Endocrinologist
at Seha Virtual Hospital and
King Salman Hospital - Hail region, Kingdom of Saudi Arabia
Sr. Clinical R&D
Clinical Research &
Director Medical Education
Learning & Innovation,
Health Economics, Reimbursement and
Patient Onboarding Programme Manager, Medtronic Diabetes, EMEA
HCP T&E Leader,
Principal Market Development
Specialist & NBMD Lead,
Medtronic Diabetes, EMEA
Program and Technology Director,
Medtronic Diabetes, EMEA
We know that in diabetes every minute counts. That’s why we designed a distinctive program to contribute to the efficiency of innovative learning.
Automated to help more patients reach glycaemic targets with less effort1,2,3,4 and no fingerpricks.*
Designed for everybody and every lifestyle.
Personalised patient outcomes.
The Smart MDI systems combines the power of real time CGM with predictive glucose alerts and personalised insulin dosing to help your patients stay ahead of their glucose levels and take the right dose at the right time.6,7
Let’s reduce the anxiety of injections together.8
Professor Tadej Battelino completed his medical degree at the University of Ljubljana in 1990. He completed a PhD focusing on glucose metabolism in neonatal endotoxic shock in 1996. He completed his clinical fellowship at Loyola University of Chicago, USA, and his postdoctoral fellowship at INSERM, Paris, France.
Professor Battelino is currently Consultant and Head of Department of Pediatric and Adolescent Endocrinology, UMC Ljubljana, Head, Chair of Pediatrics, and Professor of Paediatrics at Faculty of Medicine, University of Ljubljana. He is PI on several publicly funded research projects in the field of diabetes, endocrinology and metabolism, and was awarded the Slovene national award for research in 2014, Gold medal for research at the University of Ljubljana in 2017, the ISPAD Achievement Award in 2020, and the Presidential Medal from Children with Diabetes society in 2022. Professor Battelino serves on the editorial boards for the journals Diabetes Care, Journal of Pediatric Endocrinology and Metabolism, Acta Diabetologica, and was Editor for the European Journal of Endocrinology from 2009 to 2015. He has authored or co-authored over 327 papers in international peer-reviewed journals and participated chapters to several international books. He has a cumulative h index of 60.
Professor Battelino is a member of numerous professional associations including the American Diabetes Association (ADA), European Society for Paediatric Endocrinology (ESPE) and the International Society for Pediatric and Adolescent Diabetes (ISPAD), for which he served as President for the 35th Annual Congress. He served on the European Association for the Study of Diabetes (EASD) council and is co-organizer of sixteen annual meetings of the Advanced Technologies and Treatment of Diabetes - ATTD. He is elected Honorary member of the Italian Society for Pediatric Endocrinology and Diabetology (SIEDP) and the Hellenic Society of Pediatric and Adolescent Endocrinology (EEPEE). Professor Battelino is a member of the Slovenian Medical Academy, Slovenian Academy of Sciences and Arts (SAZU), and the European Academy of Sciences and Arts.
Professor Goran Petrovski started the national insulin pump program in 2002 in Skopje Macedonia, where as a chief for the Center for Insulin Pumps and Sensors he achieved the reimbursement of insulin pump and sensor in his country. He is a Donnell D. Etzwiler scholar at the International Diabetes Center in Minneapolis, USA and Lantus Young Investigator prize winner for clinical research in 2009 in Berlin, Germany. He’s published more than 150 papers in peer-reviewed journals and authored 6 books on type 1 diabetes, insulin pump, endocrinology test and clinical examination. Professor Petrovski is a keynote speaker for international conferences on diabetes technology in Europe, Middle East, Asia and Africa and a visiting professor for several medical schools.
Professor Goran Petrovski’s clinical and research interest focuses on Type 1 Diabetes, insulin pump and CGM with recent focus on automated insulin delivery and hybrid closed loop system. In the last 15 years, he treated more than 1,800 patient son pumps and has analyzed more than two million CGM days in patients with type 1 and type 2 diabetes, pregnancy and exercise. He organized many Diabetes Summer Camps for children with diabetes, and he is also active in using social media in diabetes (several publications).
In 2019, Professor Petrovski released his “10-Day initiation Protocol on MiniMedTM 670G” then in 2022 he published on the successful transitioning of children and adolescent with Type 1 Diabetes from Multiple Daily Injections to MiniMed™ 780G in 10 days. During ISPAD Conference, last September 2022, Professor Petrovski presented his new study on the impact of meal management simplification approach using MiniMed™ 780G system in adolescent with Type 1 Diabetes.
His goal is to simplify diabetes management and decrease the diabetes burden using technology, as well to decrease A1c level by 1% in every uncontrolled patient with type 1 diabetes for the period of one year, until they reach satisfied glucose control.
Professor Johan Jendle received his medical degree from the University of Linköping, Sweden. His did his postgraduate training in Linköping University Hospital and has specialized in endocrinology, diabetology and internal medicine. He has been principal investigator for numerous clinical trials for both type 1 and type 2 diabetes. His recent work has been focused on glucagon-like peptide-1 receptor agonists, health economy and diabetes, continuous subcutaneous insulin infusion and continuous glucose monitoring systems, smart insulin pens, diabetes and physical exercise (endurance sports, skydiving and SCUBA-diving). He has also discovered, a unique hereditary form of central diabetes insipidus, Jendles disease.
Professor Jendle has authored or co-authored more than 100 papers published in peer-reviewed journals. He is also a regular reviewer and invited speaker at local-, national- and international scientific meetings.
Professor Jendle is a member of the study group at the European Association for the Study of Diabetes Eye Complications (EASDec), the study group of physical activities at the European Association for the Study of Diabetes (ExPAS) and study group of physical activities at the Juvenile Research Diabetes Foundation (JDRF). He is also a member of the international federation of clinical chemistry (IFCC) working group on CGM.
Robert A. Vigersky, M.D. is the Chief Medical Officer of Medtronic Diabetes and Professor of Medicine at the Uniformed Services University of the Health Sciences. He graduated from Boston University School of Medicine, did his Internal Medicine training at the Johns Hopkins Hospital and completed his Endocrinology Fellowship at the National Institutes of Health.
Dr. Vigersky served as Endocrine Society President from 2009-2010 and received the Diabetes Technology Society’s Leadership Award in 2011. He has published over 345 scholarly papers and abstracts focusing on the use of technology to improve outcomes of patients with diabetes.
He on the Editorial Board of Diabetes Technology and Therapeutics and reviews manuscripts for over 20 peer-reviewed journals.
Dr. Vigersky has also had a distinguished career in the U.S. Army Medical Corps. He held the rank of Colonel before retiring in 2015. He founded the award-winning Diabetes Institute of the Walter Reed Health Care System. Dr. Vigersky received numerous military awards including the Legion of Merit. He continues to see patients and mentor Fellows and junior faculty as a Red Cross volunteer at Walter Reed.
Professor Damla Gökşen graduated from Ege University Medical School. She completed her residency in Pediatrics and her fellowship in Pediatric Endocrinology and Diabetes in Ege University Faculty of Medicine. In 2004, she worked in Pediatric Endocrinology and Diabetes Department in Yale University for 3 months to develop her skills in Type 1 diabetes technologies. She has served on numerous committees in Turkish Pediatric Endocrinology and Diabetes Society. She is working on online education of Diabetes in Turkey and also working on to develop Diabetes Registry System in Turkey. She has been chairing the Diabetes Technology Symposium in Turkey for 4 years.
She is Professor of Pediatrics in Pediatric Endocrinology and Diabetes Department at Ege University Faculty of Medicine. Her scientific interests mainly relate to type 1 diabetes treatment and technologies, monogenic diabetes, metabolic bone disease, puberty and growth disorders. Dr. Gökşen has been working on rare genetic causes of monogenic diabetes in Turkish population.
Prof. Ohad Cohen. Dr. Cohen is currently the Global Medical Affairs Director for Medtronic Diabetes. He is representing Medtronic Diabetes in European and international professional bodies as well as driving the medical field of type 1 Diabetes in the effective and safe utilization of technology for better outcomes. Prof. Cohen is leading clinical trials as well as real world analysis of the use of technology in Diabetes as well as developing and running educational programs for Health care providers and for people living with Diabetes.
Ohad Cohen is a Clinical Professor of Medicine Institute of Endocrinology, Chaim Sheba Medical Center, Sackler School of Medicine , Tel-Aviv, Israel . He received his medical degree from the Technion, Israel Institute of Technology , Haifa, Cum Laude . His Board Certification Internal Medicine and in Endocrinology and Metabolism was at the Rabin Medical Center, Israel. Prof. Cohen pursued further post Doctoral fellowships at Harvard medical school and the Mayo clinic.
Dr. Beatrix Sármán works at Semmelweis University since she finished the Medical Faculty. She has been specialized in endocrinology and diabetes. She is the head of the out-patient Clinic in the field of Endocrinology and Diabetes. Beside endocrine and rare endocrine diseases, her center takes charge of adults type 1 and type 2 Diabetes care, and also of insulin pump therapy and diabetic pregnancy. Dr. Beatrix has also an inpatient department. Her specialty is CGM, insulin pump therapy in type 1 diabetes and during pregnancy.
She is vice president of the Pregnancy Study group of the Hungarian Diabetes Association and also participates as a board member in the Insulin pump study group in Hungary.
Dr. Mohammed has the following professional qualifications:
Professor Nancy Elbarbary is Member of several professional societies, both national and international, such as International Society for Pediatric and Adolescent Diabetes (ISPAD), the European Society of Pediatric Endocrinology (ESPE), the Egyptian Society of Childhood Diabetes and Endocrinology (ESDEP), and Arab Society for Paediatric Endocrinology and Diabetes (ASPED).
Contributed to the ESPE e-learning program and participated in ISPAD Guidelines 2018 in two chapters and in the IDF-DAR Diabetes and Ramadan Practical Guidelines 2021. Also, participated in International Consortium of Polycystic Ovarian Syndrome in Adolescence and updated chapter of ISPAD Guidelines 2022. Translated web site of Beyond type 1 diabetes supported by JDRF in Egyptian Arabic language.
Is a Steering Committee member of ASPED-ISPAD Diabetes Academy since 2016 and the head of diabetes committee and scientific research in ASPED since 2018. Invited speaker at regional meetings of professional specialty societies, international meetings and symposia.
Serves as invited reviewer in more than 30 international peer-reviewed journals. Member in the Editorial Board of more than ten international journals and a member of research and ethics committee at Ain Shams University hospital, Cairo.
Published over 50 papers in international and supervised more than 60 thesis (both Master and MD), all were accepted.
Supervised and helped in the writing of " Protocol of management of DKA in Type 1 Diabetes" which is made specific for Egyptian doctors treating diabetic children.
Participated as a principal investigator in trials sponsored by Diabetes associations and is involved in many other international clinical and basic research projects as country representative of Egypt in TEENs registry study, FITTER and SWEET. Received several international professional prizes, awards, grants and special recognitions from different Egyptian Academic Societies and from the Academy of Scientific Research and Technology for distinguished international publications. Have been awarded in the name of Country’s president Abdel Fattah El-Sisi; the First-Class Medal of Honor Award for Medical Science and State Academic Recognition Achievement.
1. Carlson AL, et al. Poster # 97 at the 80th International Conference of the American Diabetes Association, June 2020, Chicago/Virtual.
2. Medtronic data on file: Pivotal Trial (Age 14-75). N=157. 16 US sites; 2020.
3. Battelino T, et al. Diabetes Care 2019; 42(8): 1593-1603.
4. ADA Guidelines of A1C<7.0 – www.Diabetes.org
5. Bosi E, et al. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemiaprone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes Endocrinol 2019;7: 462–72.
6. Abraham SB, et al. Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts. Journal of Diabetes Science and Technology 2021; 15(1):91–97
7. Smith M, et al, E5 , SIPs Improve Time Below Range in MDI Therapy, AMCP Congress 2020
8. Riley D, Raup G. Impact of a subcutaneous injection device on improving patient care. Nurs Manage. 2010;41(6):49-54
* A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
** Refer to MiniMed™ Mobile app User Guide
† Some user interaction required.
‡ If CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Refer to System User Guide
¶ Do not inject more than 75 times through a single device. This information does not substitute the Instructions for Use/User Guide. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for use.